» Articles » PMID: 36533190

Pathogenesis to Management of Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer whose incidence continues to rise in many parts of the world due to a concomitant rise in many associated risk factors, such as alcohol use and obesity. Although early-stage HCC can be potentially curable through liver resection, liver-directed therapies, or transplantation, patients usually present with intermediate to advanced disease, which continues to be associated with a poor prognosis. This is because HCC is a cancer with significant complexities, including substantial clinical, histopathologic, and genomic heterogeneity. However, the scientific community has made a major effort to better characterize HCC in those aspects via utilizing tissue sampling and histological classification, whole genome sequencing, and developing viable animal models. These efforts ultimately aim to develop clinically relevant biomarkers and discover molecular targets for new therapies. For example, until recently, there was only one approved systemic therapy for advanced or metastatic HCC in the form of sorafenib. Through these efforts, several additional targeted therapies have gained approval in the United States, although much progress remains to be desired. This review will focus on the link between characterizing the pathogenesis of HCC with current and future HCC management.

Citing Articles

Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy.

Rohland O, Freye L, Schwenk L, Ali-Deeb A, Ardelt M, Bauschke A Cancers (Basel). 2024; 16(5).

PMID: 38473282 PMC: 10930899. DOI: 10.3390/cancers16050920.

References
1.
Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B . High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39CD8 T cells. Gut. 2020; 70(10):1965-1977. PMC: 8458084. DOI: 10.1136/gutjnl-2020-322196. View

2.
Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong L . Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability. Hepatology. 2017; 65(2):678-693. PMC: 5432427. DOI: 10.1002/hep.28927. View

3.
Reparaz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B . Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer. 2022; 10(2). PMC: 9066373. DOI: 10.1136/jitc-2021-003978. View

4.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

5.
Yang J, Addissie B, Mara K, Harmsen W, Dai J, Zhang N . GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2018; 28(3):531-538. PMC: 6401221. DOI: 10.1158/1055-9965.EPI-18-0281. View